We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 674.00 | 5.94% | 12,026.00 | 12,006.00 | 12,012.00 | 12,096.00 | 11,850.00 | 11,890.00 | 4,645,537 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.26 | 186.15B |
From Apr 2019 to Apr 2024
By Ed Ballard
LONDON--U.K.-based drugmaker AstraZeneca (AZN.LN) on Monday announced a plan to invest $285 million in a new biological medicines facility in Sodertalje, Sweden.
The company said the move is the first phase of what could be a three-part investment program to expand its biologics manufacturing capabilities.
The new plant in Sodertalje--already home to AstraZeneca's biggest global tablets and capsules manufacturing plant--will begin producing protein therapeutics for clinical trials from the end of 2018, AstraZeneca said. It will start turning out commercial products when it becomes fully operational by 2019.
"This is a strategically important investment for AstraZeneca to support the accelerating development of biotech medicines, which now make up around half of our pipeline," said Chief Executive Pascal Soriot.
"We expect to bring a significantly increased number of new specialty care medicines to patients in the coming years, driven in large part by biologics. This new plant will give us greater capacity and flexibility to handle clinical trials, and will also play an important role in our future commercial production."
AstraZeneca said it will recruit between 150 and 250 highly skilled workers to staff the facility by 2019.
At 0821 GMT, shares traded 20 pence or 0.5% higher at 4,388 pence.
Write to Ed Ballard at ed.ballard@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
